This cluster converges on ferroptosis—the iron-dependent, lipid peroxidation-driven form of regulated cell death—as the central mechanistic battleground for overcoming drug resistance in hepatocellular carcinoma (HCC). Multiple independent axes feed into this common node: the TCF12-HIF-1α signaling module drives angiogenesis and sorafenib resistance, while PCDH17 overexpression reactivates ferroptotic sensitivity in lenvatinib-resistant cells, and the ER stress/HMOX1/Fe2+/ROS cascade generates the oxidative conditions necessary for ferroptotic execution. Together these pathways illustrate how liver tumors exploit parallel, converging mechanisms—angiogenic support, antioxidant buffering (GSH/GPX4), and iron/ROS regulation—to escape first-line targeted therapies (sorafenib, lenvatinib), and how experimentally reversing any one of these nodes (TCF12 knockdown, PCDH17 overexpression, erastin-induced GPX4 inactivation) restores drug sensitivity.
A key trajectory is the mechanistic dissection of resistance to approved multikinase inhibitors. TCF12 is shown to stabilize HIF-1α via direct protein-protein interaction (validated by co-immunoprecipitation), promoting CD31-correlated angiogenesis and endothelial permeability; TCF12 knockdown suppresses vascularization and sensitizes cells to sorafenib, an effect reversible by HIF-1α overexpression. This defines a therapeutically actionable axis wherein anti-angiogenic and ferroptosis-inducing strategies could be combined to counteract acquired resistance to VEGFR/PDGFR/RAF inhibition. In parallel, PCDH17 emerges as a novel ferroptosis regulator whose overexpression overcomes lenvatinib resistance, validated in xenograft models, positioning ferroptosis induction as a complementary strategy to re-sensitize refractory tumors independent of angiogenic signaling.
Mechanistically, the field is converging on a unified model of ferroptotic vulnerability governed by iron accumulation, ROS generation, and lipid peroxidation, counterbalanced by glutathione-dependent antioxidant defenses (GSH/GPX4) and enzymes like ANPEP that support cystine uptake and GSH synthesis to suppress ferroptosis. The ER stress–HMOX1–Fe2+–ROS pathway offers an additional route to ferroptotic induction, linking organelle stress responses to iron metabolism as an alternative or adjunct trigger. Erastin serves as the prototypical pharmacological tool compound validating GPX4-dependent ferroptosis induction across these models.
Collectively, this evidence base signals an emerging treatment paradigm: rather than relying solely on kinase inhibition, next-generation HCC therapy is trending toward combinatorial regimens that pair conventional targeted agents (sorafenib, lenvatinib) with ferroptosis-inducing or resistance-reversing interventions—targeting TCF12/HIF-1α-driven angiogenesis, restoring PCDH17 expression, or disrupting glutathione/antioxidant machinery—to overcome the drug resistance that currently limits clinical efficacy in advanced liver cancer.